Get the Stockscreener App
0.795
4.77%
0.0362
After Hours:
.80
0.005
+0.63%
Plus Therapeutics Inc stock is traded at $0.795, with a volume of 11.28M.
It is up +4.77% in the last 24 hours and up +138.60% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.7588
Open:
$0.7308
24h Volume:
11.28M
Relative Volume:
0.40
Market Cap:
$48.09M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.3142
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+35.90%
1M Performance:
+138.60%
6M Performance:
-35.70%
1Y Performance:
-48.71%
1-Day Range:
$0.73
$0.867
1-Week Range:
$0.5719
$0.90
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.795 | 45.96M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Arch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 Update - GlobeNewswire Inc.
Plus Therapeutics, Inc. shares rise 2.37% premarket after Almirall and Absci expand AI Drug Creation collaboration. - AInvest
Plus Therapeutics Surges 17.46% on Breakthrough FDA Clearance and Strategic Funding Boost – What’s Next for PSTV? - AInvest
Plus Therapeutics shares rise 3.34% premarket after announcing a dose escalation phase 1 study for 186RNL. - AInvest
How does Plus Therapeutics Inc. generate profit in a changing economyHarness the power of proven investment plans - Jammu Links News
What is the dividend policy of Plus Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
What is the risk reward ratio of investing in Plus Therapeutics Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
What institutional investors are buying Plus Therapeutics Inc. stockConsistent triple-digit returns - Jammu Links News
What makes Plus Therapeutics Inc. stock price move sharplyFree High-Return Strategy Alerts - Jammu Links News
What analysts say about Plus Therapeutics Inc. stockGet timely advice on market trends - Jammu Links News
What drives Plus Therapeutics Inc. stock priceExtraordinary earning power - Jammu Links News
How strong is Plus Therapeutics Inc. company’s balance sheetTop Growth Trend Scanner With High Returns - jammulinksnews.com
Published on: 2025-08-01 22:18:13 - metal.it
Plus Therapeutics (PSTV.O) Surges 16.5% — What's Behind the Sharp Move? - AInvest
Plus Therapeutics’ Innovative Study on Rhenium-186 NanoLiposome for Cancer Metastases - TipRanks
What are analysts’ price targets for Plus Therapeutics Inc. in the next 12 monthsStock Strategy Recommendation From AI Tools - jammulinksnews.com
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic - GlobeNewswire
Plus Therapeutics (PSTV) to Introduce CNSide Diagnostics in Texas by August 2025 - GuruFocus
Plus Therapeutics Provides US Launch Update for its CNSide® Diag - GuruFocus
Revolutionary CNS Cancer Test With 92% Accuracy Launches at Major Texas Cancer Centers - Stock Titan
Is Plus Therapeutics Inc. stock overvalued or undervaluedReal Time Watchlist With Proven Results - jammulinksnews.com
Plus Therapeutics (PSTV.O) Plunges 13%: Unpacking the Intraday Shock - AInvest
Institutional Tools Highlight Unusual Flow in Plus Therapeutics Inc.Watchlist for Smart Swing Trading Updated - metal.it
Does Plus Therapeutics Inc. stock perform well during market downturnsBuild wealth steadily with proven investment techniques - jammulinksnews.com
Why is Plus Therapeutics Inc. stock attracting strong analyst attentionAmplify your gains with low-risk picks - Jammu Links News
What catalysts could drive Plus Therapeutics Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - jammulinksnews.com
How volatile is Plus Therapeutics Inc. stock compared to the marketConsistent wealth multiplication - jammulinksnews.com
Published on: 2025-07-27 20:49:15 - jammulinksnews.com
Healthcare Stocks Move in Intrday Session: Gainers and Losers - AInvest
Should I buy Plus Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
Can Plus Therapeutics Inc. stock recover from recent declineFree Consultation - Jammu Links News
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):